OATP1B1, OATP1B3, and MRP2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker

Drug Metabolism and Disposition

Volumn 34, Issue 5, 2006, Pages 862-869

  Nakagomi Hagihara, Rie ^a   Nakai, Daisuke ^a   Kawai, Kenji ^a   Yoshigae, Yasushi ^a   Tokui, Taro ^a   Abe, Takaaki ^b   Ikeda, Toshihiko ^a  

^a DAIICHI SANKYO CO   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CARRIER PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; OLMESARTAN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 8; POLYPEPTIDE; SODIUM ION; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; VERLUKAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG LIVER LEVEL; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; HEPATOBILIARY SYSTEM; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; LIVER CELL; MALE; MEMBRANE VESICLE; MICHAELIS CONSTANT; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; XENOPUS LAEVIS;

ANGIOTENSIN II; ANIMALS; AREA UNDER CURVE; BILE; BILE CANALICULI; CELL LINE; CELL MEMBRANE; FEMALE; HEPATOCYTES; HUMANS; IMIDAZOLES; LIVER; MALE; MITOCHONDRIAL PROTEINS; OOCYTES; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; RATS; RATS, SPRAGUE-DAWLEY; RIBOSOMAL PROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS; TETRAZOLES; XENOPUS LAEVIS;

ANIMALIA; XENOPUS LAEVIS;

EID: 33645816996     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.008888     Document Type: Article

References (38)

1. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, et al. (1999) Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 274:17159-17163.
2. Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, et al. (2001) LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120:1689-1699.
3. Akhteruzzaman S, Kato Y, Kouzuki H, Suzuki H, Hisaka A, Stieger B, Meier PJ, and Sugiyama Y (1999) Carrier-mediated hepatic uptake of peptidic endothelin antagonists in rats. J Pharmacol Exp Ther 290:1107-1115.
4. Chan LM, Lowes S, and Hirst BH (2004) The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21:25-51.
5. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res (NY) 10:1093-1095.
6. Goldin A (1992) Maintenance of Xenopus laevis and oocyte injection. Methods Enzymol 207:266-279.
7. Groothuis GMM, Sandker GW, Prium J, Weert B, Slooff MJH, and Meijer DKF (1995) Comparison of human hepatocytes isolated from livers accepted or discarded for orthotopic transplantation. Toxicol In Vitro 9:951-958.
8. Hirouchi M, Suzuki H, Itoda M, Ozawa S, Sawada J, Ieiri I, Ohtsubo K, and Sugiyama Y (2004) Characterization of the cellular localization, expression level and function of SNP variants of MRP2/ABCC2. Pharm Res (NY) 21:742-748.
9. Hulot JS, Villard E, Maguy A, Morel V, Mir L, Tostivint I, William-Faltaos D, Fernandez C, Hatem S, Deray G, et al. (2005) A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 15:277-285.
10. Ishikawa T, Muller M, Klunemann C, Schaub T, and Keppler D (1990) ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates. J Biol Chem 265:19279-19286.
11. Ito K, Suzuki H, Horie T, and Sugiyama Y (2005) Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res (NY) 22:1559-1577.
12. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, and Otsubo K (2001) Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11:175-184.
13. Itoda M, Saito Y, Soyama A, Saeki M, Murayama N, Ishida S, Sai K, Nagano M, Suzuki H, Sugiyama Y, et al. (2002) Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5′-untranslated region and exon 28. Drug Metab Dispos 30:363-364.
14. Iwai M, Suzuki H, Ieiri I, Otsubo K, and Sugiyama Y (2004) Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 14:749-757.
15. Keitel V, Nies AT, Brom M, Hummel-Eisenbeiss J, Spring H, and Keppler D (2003) A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2) Am J Physiol 284:G165-G174.
16. Laeis P, Puchler K, and Kirch W (2001) The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl 19:S21-S32.
17. Lecureur V, Courtois A, Payen L, Verhnet L, Guillouzo A, and Fardel O (2000) Expression and regulation of hepatic drug and bile acid transporters. Toxicology 153:203-219.
18. Letschert K, Komatsu M, Hummel-Eisenbeiss J, and Keppler D (2005) Vectorial transport of the peptide CCK-8 by double-transfected MDCKII cells stably expressing the organic anion transporter OATP1B3 (OATP8) and the export pump ABCC2. J Pharmacol Exp Ther 313:549-556.
19. Meier PJ (1988) Transport polarity of hepatocytes. Semin Liver Dis 8:293-307.
20. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, and Nishimura K (2001) Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 297:861-867.
21. Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lutjohann D, von Bergmann K, Eichelbaum M, and Kivisto KT (2005) Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet Genomics 15:303-309.
22. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, et al. (2004) High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:429-440.
23. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, et al. (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554-565.
24. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, and Yokoi T (2002) Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302:804-813.
25. Olinga P, Merema MT, Meijer DKF, Slooff MJH, and Groothuis GMM (1993) Human liver slices express the same lidocaine biotransformation rate as isolated human hepatocytes. Altern Lab Anim 21:466-468.
26. Sandker GW, Weert B, Olinga P, Wolters H, Slooff MJ, Meijer DK, and Groothuis GM (1994) Characterization of transport in isolated human hepatocytes. A study with the bile acid taurocholic acid, the uncharged ouabain and the organic cations vecuronium and rocuronium. Biochem Pharmacol 47:2193-2200.
27. Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, and Sugiyama Y (2003) Function of uptake transporters for taurocholate and estradiol 17β-D-glucuronide in cryopreserved human hepatocytes. Drug Metab Pharmacokinet 18:33-41.
28. Suzuki H and Sugiyama Y (2002) Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev 54:1311-1331.
29. Takayanagi M, Sano N, and Takikawa H (2005) Biliary excretion of olmesartan, an angiotensin II receptor antagonist, in the rat. J Gastroenterol Hepatol 20:784-788.
30. Tiribelli C, Lunazzi GC, and Sottocasa GL (1990) Biochemical and molecular aspects of the hepatic uptake of organic anions. Biochim Biophys Acta 1031:261-275.
31. Tirona RG, Leake BF, Merino G, and Kim RB (2001) Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276:35669-35675.
32. Tokui T, Nakai D, Nakagomi R, Yawo H, Abe T, and Sugiyama Y (1999) Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharm Res (NY) 16:904-908.
33. Trauner M and Boyer JL (2003) Bile salt transporters: molecular characterization, function and regulation. Physiol Rev 83:633-671.
34. von Bergmann K, Laeis P, Puchler K, Sudhop T, Schwocho LR, and Gonzalez L (2001) Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens Suppl 19:S33-S40.
35. Warner GT and Jarvis B (2002) Olmesartan medoxomil. Drugs 62:1345-1356.
36. Wu CP, Klokouzas A, Hladky SB, Ambudkar SV, and Barrand MA (2005) Biochem Pharmacol 70:500-510.
37. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 264:G36-G44.
38. Yoshida K and Kohzuki M (2004) Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist. Cardiovasc Drug Rev 22:285-308.